Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?
Publication
, Journal Article
Bhat, A; Punnen, S
Published in: Oncology (Williston Park)
June 19, 2019
Duke Scholars
Published In
Oncology (Williston Park)
ISSN
0890-9091
Publication Date
June 19, 2019
Volume
33
Issue
6
Start / End Page
235 / 236
Location
United States
Related Subject Headings
- Watchful Waiting
- Risk Assessment
- Prostatic Neoplasms
- Population Surveillance
- Neoplasm Grading
- Male
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Bhat, A., & Punnen, S. (2019). Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer? Oncology (Williston Park), 33(6), 235–236.
Bhat, Abhishek, and Sanoj Punnen. “Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?” Oncology (Williston Park) 33, no. 6 (June 19, 2019): 235–36.
Bhat A, Punnen S. Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer? Oncology (Williston Park). 2019 Jun 19;33(6):235–6.
Bhat, Abhishek, and Sanoj Punnen. “Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?” Oncology (Williston Park), vol. 33, no. 6, June 2019, pp. 235–36.
Bhat A, Punnen S. Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer? Oncology (Williston Park). 2019 Jun 19;33(6):235–236.
Published In
Oncology (Williston Park)
ISSN
0890-9091
Publication Date
June 19, 2019
Volume
33
Issue
6
Start / End Page
235 / 236
Location
United States
Related Subject Headings
- Watchful Waiting
- Risk Assessment
- Prostatic Neoplasms
- Population Surveillance
- Neoplasm Grading
- Male
- Humans